Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Clinuvel Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $780.12 million
P/E Ratio 27.17
Dividend Yield 0.32%
Shares Outstanding 50.10 million
Earnings per share 0.573
Dividend per share 0.05
Year To Date Return -2.69%
Earnings Yield 3.68%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Clinuvel Pharmaceuticals Ltd (ASX: CUV)
    Latest News

    A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
    Broker Notes

    7 ASX All Ords shares elevated to 'strong buy' status in March

    There are blue chips and small caps on this list.

    Read more »

    Kid on a skateboard with cardboard wings soars along the road.
    How to invest

    Shares vs. property: Why cheaper homes and ASX small-cap shares are rising fastest in 2024

    We look into the changing trends in shares vs. property.

    Read more »

    A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
    Share Gainers

    Why Beach, Clinuvel, Deep Yellow, and EML shares are charging higher today

    These ASX shares are ending the week strongly. But why?

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Gainers

    Why Arafura, Bubs, Clinuvel, and Superloop shares are racing higher today

    Why are investors getting excited about these shares today?

    Read more »

    Man with rocket wings which have flames coming out of them.
    Broker Notes

    These ASX shares could rise 30% to 50% in 12 months

    Big returns could be on the cards for owners of these shares according to analysts.

    Read more »

    A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
    Share Fallers

    Why Clinuvel, Medibank, Sayona Mining, and Tabcorp shares are sinking today

    These ASX shares are out of favour with investors on Thursday. But why?

    Read more »

    A cute young girl wearing gumboots and play clothes holds open the door of her wooden cubby house as she sits and smiles in a backyard outdoor setting.
    How to invest

    Is buying investment property in regional areas like buying ASX small-cap shares?

    Will population changes and economic growth in the regions lead to more people buying investment properties there? And is this…

    Read more »

    A man holding a cup of coffee puts his thumb up and smiles while at laptop.
    Small Cap Shares

    Morgans names 7 small-cap ASX shares to buy for earnings season

    Here are a number of small caps that the broker has given the thumbs up to this week.

    Read more »

    a woman holds a facebook like thumbs up sign high above her head. She has a very happy smile on her face.
    Growth Shares

    Big returns could be coming for these ASX growth shares in 2024

    Analysts think these growth stocks could be good portfolio additions this year.

    Read more »

    A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
    Growth Shares

    Looking for ASX growth shares to buy? These could rise ~30%

    Analysts are tipping big returns for shareholders of these growing companies.

    Read more »

    A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
    Broker Notes

    Buy these 4 ASX 300 shares, say top brokers

    Market analysts have upgraded their ratings on these four ASX 300 shares today.

    Read more »

    Couple looking at their phone surprised, symbolising a bargain buy.
    Broker Notes

    Brokers name 3 ASX shares to buy now

    Here's why brokers are feeling bullish about these three shares this week.

    Read more »

    Frequently Asked Questions

    Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.

    Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.

    Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.

    Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    05 Sep 2023 $0.0500 100.00% Final 20 Sep 2023
    06 Sep 2022 $0.0400 100.00% Final 21 Sep 2022
    02 Sep 2021 $0.0250 0.00% Final 17 Sep 2021
    03 Sep 2020 $0.0250 0.00% Final 18 Sep 2020
    04 Sep 2019 $0.0250 0.00% Final 19 Sep 2019
    21 Sep 2018 $0.0200 0.00% Final 08 Oct 2018

    CUV ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Clinuvel Pharmaceuticals Ltd

    Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.

    Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.

     

    CUV Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 May 2024 $15.57 $0.17 1.10% 48,359 $15.38 $15.63 $15.25
    23 May 2024 $15.40 $0.38 2.53% 51,563 $15.00 $15.52 $15.00
    22 May 2024 $15.02 $-0.43 -2.78% 61,584 $15.40 $15.60 $15.00
    21 May 2024 $15.45 $0.06 0.39% 48,398 $15.34 $15.51 $15.18
    20 May 2024 $15.39 $-0.06 -0.39% 34,804 $15.46 $15.49 $15.12
    17 May 2024 $15.45 $0.19 1.25% 109,537 $15.26 $15.59 $15.20
    16 May 2024 $15.26 $0.18 1.19% 74,738 $15.14 $15.31 $15.01
    15 May 2024 $15.08 $-0.54 -3.46% 76,813 $15.40 $15.56 $15.03
    14 May 2024 $15.62 $0.46 3.03% 97,417 $15.08 $15.67 $15.08
    13 May 2024 $15.16 $-0.05 -0.33% 40,131 $15.20 $15.21 $14.90
    10 May 2024 $15.21 $0.30 2.01% 60,345 $14.92 $15.28 $14.92
    09 May 2024 $14.91 $-0.56 -3.62% 61,862 $15.49 $15.50 $14.90
    08 May 2024 $15.47 $0.08 0.52% 54,127 $15.34 $15.59 $15.27
    07 May 2024 $15.39 $0.39 2.60% 66,623 $15.00 $15.60 $15.00
    06 May 2024 $15.00 $0.14 0.94% 41,423 $14.85 $15.08 $14.85
    03 May 2024 $14.86 $0.00 0.00% 45,805 $14.93 $15.07 $14.76
    02 May 2024 $14.86 $-0.20 -1.33% 76,148 $15.07 $15.10 $14.83
    01 May 2024 $15.06 $0.01 0.07% 70,978 $15.10 $15.29 $15.00
    30 Apr 2024 $15.05 $-0.27 -1.76% 33,809 $15.29 $15.35 $15.01
    29 Apr 2024 $15.32 $0.75 5.15% 77,127 $14.90 $15.32 $14.70
    26 Apr 2024 $14.57 $-0.42 -2.80% 54,613 $15.02 $15.20 $14.56

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    24 Nov 2023 Philippe Wolgen Buy 301,125 $5,119,125
    Conversion of securities.
    24 Nov 2023 Philippe Wolgen Transfer 3,124,097 $53,109,649
    Off-market transfer. Assuming off market transfer of shares
    24 Nov 2023 Philippe Wolgen Expiry 1,212,625 $20,614,625
    As advised by the company. Lapsed, 3,01,125 Rights
    24 Nov 2023 Philippe Wolgen Transfer 3,124,097 $53,109,649
    Off-market transfer. Assuming off market transfer of shares
    24 Nov 2023 Philippe Wolgen Exercise 301,125 $5,119,125
    Conversion of securities.
    19 Sep 2023 Philippe Wolgen Buy 1,850 $29,813
    On-market trade.
    26 Jun 2023 Philippe Wolgen Transfer 3,120,715 $53,894,748
    Off-market transfer. Assuming off-market transfer of shares
    26 Jun 2023 Philippe Wolgen Buy 1,532 $27,147
    On-market trade.
    26 Jun 2023 Philippe Wolgen Transfer 3,120,715 $53,894,748
    Off-market transfer. Assuming off-market transfer of shares

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Brenda Mary Shanahan Non-Executive Director Dec 2007
    Mrs Shanahan has more tha 20 year's of experience in medical R&D and commercialisation. She is currently a non executive director of Phoslock Water Solutions Ltd
    Mrs Susan (Sue) Smith Non-Executive Director Sep 2019
    Mrs Smith is the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages a consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors. Prior to her current roles Mrs Smith has a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Based in London, Mrs Smith is also Non-Executive Board Chair of Women's Health (London West One) Ltd, a specialist medical practice, Non-Executive Director of Elite Medicine Ltd, a precision medicine company, and a Trustee of the HCA International Foundation.
    Dr Philippe J Wolgen Chief Executive OfficerManaging Director Dec 2005
    Dr Wolgen is currently leading the Group's expansion, with an immediate focus on the US and the further development of the product pipeline for various market segments. His focus has been to establish a professional management team to execute the corporate objectives set and prepare next generation of managers.
    Dr Karen Agersborg Non-Executive Director Jan 2018
    Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital. Dr Agersborg had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Dr Agersborg is also integral to setting US commercial strategy, pending US approval of SCENESSE, a decision on an approval expected later in 2019.
    Dr Jeffrey Rosenfeld Non-Executive ChairmanNon-Executive Director Nov 2019
    Dr Rosenfeld has experience in senior healthcare and research executive roles and career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands. One of Australia's senior and experienced military surgeons, Dr Rosenfeld served on eight deployments to Rwanda, Bougainville, East Timor, the Solomon Islands and Iraq. Having attained the rank of Major General, Dr Rosenfeld is also a former Surgeon General of the Australian Defence Force and remains active in defence and veterans' affairs organisations.In 2018, he received the International Lifetime Recognition Award of the American Association of Neurological Surgeons.
    Dr Emilie Rodenburger Non-Executive Director Apr 2024
    Dr Rodenburger previously worked with the CLINUVEL Group for over a decade in clinical development roles in Australia, the USA and Europe. Dr Rodenburger spent four years with Roche in senior clinical roles. Based in the UK, Dr Rodenburger will oversee CLINUVEL global clinical program.
    Mr Darren Keamy Chief Finance OfficerCompany Secretary Dec 2005
    -
    Darren Keamy Chief Finance OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Ltd 11,280,990 22.83%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 5,679,762 11.50%
    BNP Paribas Nominees Pty Ltd 5,312,764 10.75%
    J P Morgan Nominees Australia Pty Ltd 4,390,776 8.89%
    Dr Philippe Jacques Wolgen 3,122,247 6.32%
    Citicorp Nominees Pty Ltd 3,014,759 6.10%
    Ender 1 LLC 2,590,824 5.24%
    BNP Paribas Nominees Pty Ltd (ii) 1,482,356 3.00%
    Emilino Group Pty Ltd 603,447 1.22%
    National Nominees Ltd 548,371 1.11%
    Dr Mark Edwin Badcock 440,085 0.89%
    Mr David William Trevorrow 229,600 0.46%
    Mr David John Lewis 187,000 0.38%
    HSBC Custody Nominees (Australia) Ltd a/c 2 180,199 0.36%
    Mr Trent Sheldon Redding 179,480 0.36%
    Mr Darren Michael Keamy 178,588 0.36%
    Rusty Hammer Pty Ltd 156,892 0.32%
    Dr Dennis Wright 156,874 0.32%
    Mr Simon John Bown 146,000 0.30%
    BNP Paribas Noms (NZ) Ltd 130,710 0.26%

    Profile

    since

    Note